Bay Colony Advisory Group, Inc D Arvinas, Inc. Transaction History

Bay Colony Advisory Group, Inc D

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$60.27 - $81.57 $158,208 - $214,121	-2,625 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$73.2 - $107.87 $69,540 - $102,476	-950 Reduced 26.57%	2,625 $216,000
Q2 2021 Jul 22, 2021	BUY	$60.45 - $84.26 $216,108 - $301,229	3,575 New	3,575 $275,000
Q1 2021 May 13, 2021	SELL	$58.19 - $91.37 $176,024 - $276,394	-3,025 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$20.19 - $84.93 $61,074 - $256,913	3,025 New	3,025 $257,000

228

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $995M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Bay Colony Advisory Group, Inc D, based on Form 13F filings with the SEC.

Stay updated on Bay Colony Advisory Group, Inc D with notifications on news.